Complete Reference

Every GLP-1 Medication, Compared

Complete 2026 comparison chart

A side-by-side comparison of every major FDA-approved GLP-1 medication based on published clinical trial data and FDA labels. This is informational only — consult your healthcare provider before making any medication decisions.

About This Comparison

All data below comes from FDA-approved labels and published clinical trial results. Clinical trials had different designs, patient populations, and durations — results across different trials cannot be directly compared. Weight loss percentages reflect trial averages; individual results vary significantly. This is not a recommendation for any medication. Only your healthcare provider can determine which medication is appropriate for you.

Complete Comparison Chart

Every major FDA-approved GLP-1 medication at a glance.

Scroll horizontally to view all medications.

Medication
Ozempic
Wegovy Injection
Wegovy Pill
Wegovy HD
Mounjaro
Zepbound
Rybelsus
Saxenda
Active Ingredient
Semaglutide
Semaglutide 2.4mg
Oral semaglutide 25mg
Semaglutide 7.2mg
Tirzepatide
Tirzepatide
Oral semaglutide
Liraglutide
Drug Class
GLP-1 RA
GLP-1 RA
GLP-1 RA
GLP-1 RA
Dual GLP-1/GIP
Dual GLP-1/GIP
GLP-1 RA
GLP-1 RA
FDA Indication
Type 2 diabetes
Weight management
Weight management
Weight management
Type 2 diabetes
Weight management
Type 2 diabetes
Weight management
Administration
Weekly injection
Weekly injection
Daily tablet
Weekly injection
Weekly injection
Weekly injection
Daily tablet
Daily injection
Frequency
Once weekly
Once weekly
Once daily
Once weekly
Once weekly
Once weekly
Once daily
Once daily
FDA Approval
2017
2021
Dec 2025
Mar 2026
2022
2023
2019
2014
Key Trial
SUSTAIN
STEP 1
OASIS 4
Higher dose data
SURPASS
SURMOUNT-1
PIONEER
SCALE
Avg Weight Loss (Trial)
Secondary endpoint
~14.9%
~16.6%
TBD
Varies by dose
~20.9%
Modest
~8%
Manufacturer
Novo Nordisk
Novo Nordisk
Novo Nordisk
Novo Nordisk
Eli Lilly
Eli Lilly
Novo Nordisk
Novo Nordisk
Approx List Price
~$935/mo
~$1,349/mo
Starting ~$149/mo
TBD
~$1,023/mo
~$1,059/mo
~$935/mo
~$1,349/mo

Individual Medication Details

Ozempic
Active IngredientSemaglutide
Drug ClassGLP-1 RA
FDA IndicationType 2 diabetes
AdministrationWeekly injection
FrequencyOnce weekly
FDA Approval2017
Key TrialSUSTAIN
Avg Weight Loss (Trial)Secondary endpoint
ManufacturerNovo Nordisk
Approx List Price~$935/mo
Wegovy Injection
Active IngredientSemaglutide 2.4mg
Drug ClassGLP-1 RA
FDA IndicationWeight management
AdministrationWeekly injection
FrequencyOnce weekly
FDA Approval2021
Key TrialSTEP 1
Avg Weight Loss (Trial)~14.9%
ManufacturerNovo Nordisk
Approx List Price~$1,349/mo
Wegovy Pill
Active IngredientOral semaglutide 25mg
Drug ClassGLP-1 RA
FDA IndicationWeight management
AdministrationDaily tablet
FrequencyOnce daily
FDA ApprovalDec 2025
Key TrialOASIS 4
Avg Weight Loss (Trial)~16.6%
ManufacturerNovo Nordisk
Approx List PriceStarting ~$149/mo
Wegovy HD
Active IngredientSemaglutide 7.2mg
Drug ClassGLP-1 RA
FDA IndicationWeight management
AdministrationWeekly injection
FrequencyOnce weekly
FDA ApprovalMar 2026
Key TrialHigher dose data
Avg Weight Loss (Trial)TBD
ManufacturerNovo Nordisk
Approx List PriceTBD
Mounjaro
Active IngredientTirzepatide
Drug ClassDual GLP-1/GIP
FDA IndicationType 2 diabetes
AdministrationWeekly injection
FrequencyOnce weekly
FDA Approval2022
Key TrialSURPASS
Avg Weight Loss (Trial)Varies by dose
ManufacturerEli Lilly
Approx List Price~$1,023/mo
Zepbound
Active IngredientTirzepatide
Drug ClassDual GLP-1/GIP
FDA IndicationWeight management
AdministrationWeekly injection
FrequencyOnce weekly
FDA Approval2023
Key TrialSURMOUNT-1
Avg Weight Loss (Trial)~20.9%
ManufacturerEli Lilly
Approx List Price~$1,059/mo
Rybelsus
Active IngredientOral semaglutide
Drug ClassGLP-1 RA
FDA IndicationType 2 diabetes
AdministrationDaily tablet
FrequencyOnce daily
FDA Approval2019
Key TrialPIONEER
Avg Weight Loss (Trial)Modest
ManufacturerNovo Nordisk
Approx List Price~$935/mo
Saxenda
Active IngredientLiraglutide
Drug ClassGLP-1 RA
FDA IndicationWeight management
AdministrationDaily injection
FrequencyOnce daily
FDA Approval2014
Key TrialSCALE
Avg Weight Loss (Trial)~8%
ManufacturerNovo Nordisk
Approx List Price~$1,349/mo
Drug Classes

Semaglutide vs Tirzepatide

The two main active ingredients in today's GLP-1 landscape work differently. Semaglutide targets GLP-1 receptors only, while tirzepatide is a dual-agonist targeting both GLP-1 and GIP receptors. Clinical trials have shown different average weight loss outcomes, though direct comparison across trials is unreliable.

Read full comparison
Formulations

Oral vs Injectable

Most GLP-1 medications are weekly injections, but oral options are expanding. The Wegovy pill and Rybelsus are currently available in oral form, with orforglipron (Eli Lilly) under FDA review. Each formulation has distinct practical trade-offs in terms of convenience, dosing, and clinical data maturity.

Read full comparison

Important Note About This Data

This table presents published data from FDA labels and clinical trials. Clinical trials for each medication had different designs, patient populations, inclusion criteria, and durations — results across different trials cannot be directly compared. Weight loss percentages are trial averages; individual results vary significantly. Pricing reflects approximate list prices and does not account for insurance, savings programs, or pharmacy discounts. Only your healthcare provider can determine which medication is appropriate for you.

Medical Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before making any decisions about your health or medications.

Frequently Asked Questions

Common questions about GLP-1 medications.

Which GLP-1 medication is most effective for weight loss?

Clinical trials have shown varying levels of weight loss across different GLP-1 medications. Tirzepatide (Zepbound) showed approximately 20.9% average weight loss in SURMOUNT-1, while semaglutide (Wegovy injection) showed approximately 14.9% in STEP 1. However, these were separate trials with different populations and cannot be directly compared. Individual responses vary significantly, and your healthcare provider can help determine which option is appropriate for you.

What is the newest GLP-1 medication?

As of early 2026, the most recent GLP-1 approvals include the Wegovy pill (oral semaglutide 25mg, approved December 2025) and Wegovy HD (semaglutide 7.2mg injection, approved March 2026). Eli Lilly's orforglipron, an oral non-peptide GLP-1, is currently under FDA review.

Are all GLP-1 medications injections?

No. While most GLP-1 medications are injections, oral options exist. Rybelsus (oral semaglutide) is approved for type 2 diabetes, and the Wegovy pill (oral semaglutide 25mg) is approved for weight management. Eli Lilly's orforglipron, another oral option, is under FDA review. The trend is toward more oral options becoming available.

Which GLP-1 medication is the cheapest?

The Wegovy pill launched with a starting price around $149/month through manufacturer savings offers, making it the most affordable branded option at list price. However, actual out-of-pocket costs depend on insurance coverage, pharmacy, and available savings programs. Some medications may be better covered by certain insurance plans.

Does Dose AI track all of these medications?

Yes. Dose AI tracks any GLP-1 medication regardless of brand or formulation. Whether you take Ozempic, Wegovy, Mounjaro, Zepbound, or any other GLP-1, the app helps you log doses, track symptoms, monitor weight changes, and manage your nutrition.

Track Any GLP-1 Medication

No matter which GLP-1 you're on, Dose AI tracks your doses, symptoms, weight, and nutrition in one place.

Free download · iOS · Premium features available